Pharma News in Brief

Akorn got UDSFDA Approval on Diclofenac Sodium Ophthalmic Solution 0.1%
Akorn announced that the USFDA has granted approval to market Diclofenac Sodium Ophthalmic Solution, 0.1%. Diclofenac Sodium Ophthalmic Solution is a non-steroidal anti-inflammatory agent used to treat cataract and refractive surgery patients. Annual sales for Diclofenac Sodium Ophthalmic Solution were approximately $14 million in 2007, according to IMS sales data.
Alcon's olopatadine nasal spray gets USFDA approval
Alcon announced that USFDA has approved Patanase (Olopatadine hydrochloride) nasal spray for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older. This product will be in the market from May onwards.
Dabur sold majority stake to Fresenius
Indian based Dabur announced that its founders and other shareholders have agreed to sell 73.27% in the company to Fresenius Kabi (Singapore) which is a unit of European firm Fresenius SE. Earlier, Dabur had sold its non-oncology drugs business to Vadodra based pharma firm Alembic to focus on cancer treatment drugs.